ホーム > 研究者の方 > 本データベースを活用した研究の紹介

本データベースを活用した研究の紹介

  1. Yamazaki K, Goto M, Koinuma S, Hishinuma K, Yamazaki S, Murashima A, Ishii I:Cohort Study of Pregnancy Outcomes After Exposure to Fexofenadine or Olopatadine in the First Trimester.Congenit Anom (Kyoto). 2026;66(1):e70056
  2. Suzuki T, Goto M, Anzai T, Yamane R, Watanabe O, Takahashi K, Murashima A:Clarithromycin Use in the First Trimester Is Not Associated With Fetal Abnormalities.Congenit Anom (Kyoto). 2026;66(1):e70041
  3. Fujioka I, Goto M, Anzai T, Takahashi K, Koinuma S, Murashima A:Pregnancy and neonatal outcomes following statin exposure in early pregnancy: a nationwide consultation-based cohort study in Japan.BMC Pregnancy Childbirth. 2026;26(1):449
  4. Hirasawa Y, Tagashira H, Ueno A, Tasaka Y, Goto M*, Murashima A, Yamamoto H: Maternal Mosapride Citrate Hydrate Exposure During the First Trimester: Assessing Risks for Congenital Anomalies. Dig Dis Sci.2025 Nov;70(11):3857-3862. *Corresponding author
  5. Hongoh M, Fujioka I, Goto M, Yamane R, Tamaki H, Murashima A, Yano T: Evaluation of the Safety of Lansoprazole Exposure During Early Pregnancy: A Prospective Cohort Study Using Two-Center Counseling Data in Japan. Yakugaku Zasshi. 2025;145(12):967-973
  6. Usuda M, Jwa SC, Goto M, Kobayashi M, Nagano H, Yakuwa N, Yamane R, Murashima A, Makabe H: Risk of major birth defects after first-trimester exposure to carbocisteine and ambroxol: A multicenter prospective cohort study using counseling data for drug safety during pregnancy. Congenit Anom (Kyoto). 2024;64(3):91-98
  7. Miki Y, Koga Y, Taogoshi T, Itamura R, Yokooji T, Hishinuma K, Yakuwa N, Goto M, Murashima A, Matsuo H: Assessment of the Safety of Exposure to Cefcapene Pivoxil during the First Trimester of Pregnancy: A Prospective Cohort Study in Japan. Biol Pharm Bull. 2024;47(7):1301-1306
  8. Goto M, Anzai T, Yamane R, Yakuwa N, Takahashi K, Murashima A: Pregnancy outcomes after first-trimester exposure to fluoroquinolones: Findings based on an integrated database from two Japanese institutions. Congenit Anom (Kyoto). 2024;64(5):199-206
  9. Nishimura A, Furugen A, Kobayashi M, Takekuma Y, Yakuwa N, Goto M, Hayashi M, Murashima A, Sugawara M: Effects of famotidine use during pregnancy: an observational cohort study. J Pharm Health Care Sci. 2024;10(1):70
  10. Honma M, Suzuki N, Goto M, Obara T, Saito Y, Nakajima K, Yamane R, Takahashi K, Nakayama T, Hayashi M, Murashima A, Toyama A: A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan. Congenit Anom (Kyoto). 2025;65(1):e12588
  11. Hatakeyama S, Goto M, Yamamoto A, Ogura J, Watanabe N, Tsutsumi S, Yakuwa N, Yamane R, Nagase S, Takahashi K, Kosaki R, Murashima A, Yamaguchi H:The safety of pranlukast and montelukast during the first trimester of pregnancy: A prospective, two-centered cohort study in Japan.Congenit Anom (Kyoto). 2022;62(4):161-168
  12. Yamaguchi Y, Yamada T, Goto M, Kawasaki H, Wada T, Ikeda-Sakai Y, Saito Y, Hayashi M, Tanaka S, Takahashi R, Nakayama T, Murashima A, Kosugi S:
    Analysis of triptan use during pregnancy in Japan: A case series.
    Congenit Anom (Kyoto). 2022;62(2):78-81
  13. Hishinuma K, Yamane R, Yokoo I, Arimoto T, Takahashi K, Goto M, Saito Y, Nakajima K, Murashima A, Hayashi M:Pregnancy outcome after first trimester exposure to domperidone—An observational cohort study.J Obstet Gynaecol Res. 2021;47(5):1700-1707